ResMed Inc. with ticker code (RMD) have now 11 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $238.00 and $180.00 suggesting an average Analsyt target price of $214.60. Given that the stocks previous close was at $210.35 and the analysts are correct then there would likely be a percentage uptick in value of 2.0%. There is a 50 day moving average of $206.14 while the 200 day moving average is $176.11. The company has a market capitalization of 31.18B. The current share price for the company is: $212.27 USD
The potential market cap would be $31,814,005,570 based on the market consensus.
The company has a dividend yield of 2.05%. Other points of data to note are a P/E ratio of 32.66, revenue per share of $31.18 and a 11.91% return on assets.
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. It also offers software solutions for a variety of out-of-hospital care providers. The Company has two segments: Sleep and Respiratory Care and the Software-as-a-Service. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company’s portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices and cloud-based software informatics solutions.
